P atient perception of symptom improvement is central to clinical care and important in the treatment of fecal incontinence (FI), a disorder that is known to degrade quality of life for affected women. Patient-physician conversation usually suffices for routine clinical care; however, research requires the use of valid, reliable, and responsive instruments that measure health-related quality of life (HRQOL) and symptom severity. Multiple instruments are available to measure severity and HRQOL for patients with FI. 1 The St Mark's Score 2 and the FI Severity Index (FISI) 3 are 2 psychometrically robust instruments for assessing symptom severity. Other patient-reported outcome measures that can be used for patients with FI include the Modified Manchester Health Questionnaire (MMHQ), 4 the Pelvic Floor Distress Inventory (PFDI), and the Pelvic Floor Impact Questionnaire (PFIQ). The PFDI and PFIQ are comprehensive questionnaires for women with pelvic floor disorders. The Colorectal-Anal Distress Inventory (CRADI) and the Colorectal-Anal Impact Questionnaire (CRAIQ) are colorectal scales within the PFDI and PFIQ that measure symptom bother and life impact of lower gastrointestinal tract complaints, respectively. 5 Despite progress in assessing HRQOL, use of these validated instruments is limited without an understanding of whether changes in an instrument's score are associated with clinically meaningful improvements by patients. The smallest change in score that is associated with a clinically meaningful improvement is called the minimum clinically important difference (MID). 6 A scale's MID is essential knowledge for appropriate interpretation of within-group changes or between-group differences in patientcentered outcomes research.
The objective of this study was to estimate the MID using both anchor-based and distribution-based approaches for the FISI, CRADI, CRAIQ, and the MMHQ in women receiving nonsurgical or surgical management of FI.
MATERIALS AND METHODS
This was an ancillary analysis of the Adaptive Behaviors among women with Bowel Incontinence (ABBI) study, a multicenter prospective cohort study, conducted by the Pelvic Floor Disorders Network, a clinical trials network funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, consisting of 7 clinical sites and a data coordinating center. The ABBI study investigated adaptive behaviors among women receiving nonsurgical or surgical management for FI per usual care practice, including behavioral techniques, pelvic floor muscle exercises, medications, surgery, or a combination of these treatments. Women were eligible if they had a primary complaint of FI consisting of liquid stool, solid stool, or mucus occurring at least monthly for 3 consecutive months and were planning to have treatment of FI. Each clinical site and the data coordinating center received institutional review board approval, and all subjects provided written informed consent.
Subjects completed several questionnaires including patient characteristics, previous treatments of FI, the Bristol Stool Form Scale to assess stool consistency, and several self-administered questionnaires to assess bowel symptom severity and HRQOL including the FISI, CRADI, CRAIQ, and MMHQ at baseline. Three and 12 months after the initiation of treatment, a Global Impression of Change scale was completed, in addition to repeating the 4 FI scales. Only those subjects who received FI treatment and completed at least 1 of the 4 scales at both the baseline and 3-month follow-up evaluations were included in this analysis.
The MMHQ is a validated questionnaire for HRQOL in women with FI. 4 It measures 8 domains (31 questions) including general health, incontinence impact, role, physical function, social function, personal function, emotional problems, sleep, energy, and the severity, which is assessed using the FISI. Total scores and scores for specific domains are measured on a 5-point scale ranging from 1 indicating ''never'' to 5 indicating ''always.'' Total scores and domain scores both range from 0 to 100. The MMHQ was chosen for HRQOL measurement over the fecal incontinence quality of life scale based on a previous validation study among women with pelvic floor disorders. 4 As part of the US English modification of the MMHQ, the FISI is contained within the MMHQ. The FISI is composed of 4 questions on incontinence of gas, mucus, liquid stool, and solid stool. 3 There are 2 highly correlated subscales that have been developed for the FISI, 1 from the patient's perspective of bother and 1 from the doctor's perspective of bother. For this study, all questionnaires were administered by telephone via a central interviewing center. Patients are asked to indicate the frequency of symptoms experienced using the following scale: 2 or more times a day, once a day, 2 or more times a week, once a week, 1 to 3 times per month, or never. Responses are weighted on a 1 to 20 severity scale, and a total FISI score is calculated from the patient's and surgeon's perspectives. Although the FISI score has a weighted scoring scale and has been validated, it lacks responsiveness data limiting its use in interventional studies.
The PFDI and the PFIQ, 5 each with 3 scales (urinary, colorectal, and pelvic organ prolapse), are condition-specific quality of life instruments developed to broadly assess pelvic floor disorders in women. They are available in long-form and short-form versions and have each been shown to be psychometrically valid, reliable, and responsive to change. 5,7Y9 These instruments are based on the structure and content of 2 widely used condition-specific quality of life questionnaires for women with lower urinary tract dysfunction, the Urogenital Distress Inventory and the Incontinence Impact Questionnaire, originally described by Shumaker et al. 10 The content to measure bowel dysfunction was modified from these original urinary incontinence questionnaires, which are called the CRADI and the CRAIQ. The 4 validated FI measures have ranges as follows: FISI, 4 to 59; CRADI, 0 to 400; CRAIQ, 0 to 400; and MMHQ, 0 to 100. In all measures, a higher score indicates worse symptom bother or greater impact of symptoms on daily functioning.
A variety of methods have been used to determine MID, and no single method has proven to be superior. 6 These methods can be separated into 2 different categoriesVanchor-based methods and distribution-based methods. Anchor-based methods determine clinically meaningful changes in relation to an external indicator, an independent ''anchor'' that has clinical relevance to the outcome; in contrast, distribution-based methods evaluate the meaningfulness of changes based on the statistical characteristics of a population and relate clinical significance to statistical parameters of the obtained sample, such as sample variability (eg, baseline variation for effect size) or reliability (eg, Cronbach > coefficient used in the SE of measurement [SEM]). 6,11Y13 In this study, we used both anchor-based and distributionbased approaches and then considered all estimates to determine the MID for each of the FI measures. For the anchor-based approach, we used the Global Impression of Change scale as the primary anchor. 13 When calculating an MID, it is important to identify the subset of people who have experienced minimal change. 13 Patients who report getting ''a little better'' constitute the minimal change subgroup. 13 For this study, the smallest change on the Global Impression of Change scale was defined as the difference in mean change in scores (from baseline to 3 months) between those who indicated that they were a little better and those who reported ''no change'' on the Global Impression of Change scale. 13 To assess the usefulness of the anchor, the correlation between the Global Impression of Change at 3 months and the change from baseline to 3 months in each of the FI measures was calculated. If the correlation coefficient was significantly greater than 0.3, a cutoff value for a moderate association, the anchor-based analysis was performed. 13 In addition, some investigators have recommended to estimate the MID based on several anchor-based methods, with relevant clinical or patient-based indicators. 13 Therefore, we also estimated the MID of the CRADI (long and short versions), CRAIQ (long and short versions), and MMHQ using the results of the FISI as an anchor, with the MID defined as an improvement from no change to 1 level of improvement in the FISI. The FISI was added as secondary anchor, in addition to the Global Impression of Change, to provide a second external patient-reported clinical anchor to estimate the MID of the remaining instruments.
For the distribution-based approaches, we determined the change from baseline to 3 months in scale scores that corresponded to an effect size of 0.5 baseline SD (1/2 SD), which is considered a conservative estimate of MID for patient-reported questionnaires, and 1 SEM, also shown to be a valid estimate of MID. 6, 11, 12, 14 The effect size was based on the baseline variation of the sample representing a standardized measure of change over time. 6, 11, 12 The SEM based on the measurement precision of the instrument was calculated by the product of the baseline SD and the square root of 1 minus its reliability coefficient, estimated using Cronbach > coefficient in this analysis (1 SEM = baseline SD Â square root [1 j Cronbach > at baseline]). 6, 11, 12, 14 The 95% confidence interval (CI) was also estimated for each approach. The 95% CI for the anchor-based MID was based on the standard 95% CI for the difference between 2 population means; for the distribution-based 0.5 SD, it was the standard 95% CI for the population variance. 15 The 95% CI for distributionbased 1 SEM was constructed using the bootstrap resampling approach. 16 For each FI measure, the anchor-based and the distribution-based MID estimates along with the 95% CI's were compared based on triangulation, a well-recognized integrated system that makes use of multiple methods to hopefully converge on a small range of values (or 1 single value). 6, 13 The recommended MIDs were selected for the FISI, CRADI (long and short versions), CRAIQ (long and short versions), and MMHQ. Analyses were performed in SAS 9.2 for Windows 
RESULTS
Eighty-three (62%) of the 133 women participating in the ABBI study completed at least 1 of the 4 FI scales at both baseline and 3 months after receiving FI treatments per routine clinical care and are the subjects of this analysis. Of these, 100% completed the FISI and CRADI, 92% the CRAIQ, and 80% the MMHQ. Subjects had a mean age (SD) of 59 (13) years, a median (range) parity of 2 (9) deliveries, and most were white (86%). When comparing the ABBI women who were eligible for this analysis (n = 83) with those who were not (n = 50), there were no significant differences in baseline demographics, medical and smoking history, typical stool consistency as characterized by the Bristol Stool Scale, or prior treatments of FI (P 9 0.1; Table 1 ).
Multiple different FI therapies were received by participants, with several having more than 1 therapy, including medications (n = 46), pelvic floor exercises (n = 39), surgery (n = 20), biofeedback (n = 10), and ''other'' (n = 6) per usual care. Overall, significant improvements in FI symptom severity and in HRQOL were observed on all measures 3 months after these interventions compared with baseline (P G 0.0001). Mean changes (SD) in FISI, CRADI (long and short versions), CRAIQ (long and short versions), and MMHQ scores were j8.8 (12.0), j52.7 (70.0) and j16.03 (21.5), j60.6 (90.0) and j17.04 (25.6), and j12.6 (19.2), respectively.
Changes from baseline to 3 months after treatment in scale scores are presented in Table 2 , stratified by patients' perception of degree of symptom improvement as measured by the Global Impression of Change. The Global Impression of Change and each of the instruments showed correlations above the established threshold of r = 0.3. The anchor-based MID (95% CI) estimates suggested by an improvement from no change to a little better for the FISI, CRADI (long and short versions), CRAIQ (long and short versions), and MMHQ are shown in Table 2 . These final anchor-based MID estimates were j3.6, j11.4 and j4.7, j18.1 and j8.0, and j3.2 for the FISI, CRADI (long and short version), CRAIQ (long and short version), and MMHQ, respectively ( Table 2) .
Using a distribution-based method, the MID (95% CI) estimates corresponding to a medium (0.5 SD) effect size and the MID estimates corresponding to 1 SEM are demonstrated in Table 3 . Although the MIDs using the 0.5 SD and 1 SEM approaches in Table 3 may seem slightly different for some measures, their respective 95% CIs overlap one another.
The MID estimates for the CRADI, CRAIQ, and MMHQ were also calculated using the degree of improvement in FI severity level as the anchor. The MID (95% CI) estimates suggested by an improvement from no change to 1 level of improvement in the FISI were as follows: j9.11 (j19.7 to 1.5) and j21.6 (j55.0 to 11.9) for CRADI (short and long versions), j5.9 (j20.9 to 9.2) and j11.5 (j59.6 to 36.7) for CRAIQ (short and long versions), and j7.1 (j15.7 to 1.4) for MMHQ (Table 4 ).
Both the anchor-based and distribution-based estimates for the MIDs of the 4 scales (with 95% CI) are illustrated graphically based on the triangulation methodology in Figure 1 . Here, the MID estimate corresponding to 0.5 SD effect size generally seems most conservative, whereas the MID estimate corresponding to 1 SEM closely shadowed the anchor-based estimate. Final MIDs of the scales reflect only the anchor-based estimates using the Global Impression of Change scale.
DISCUSSION
Patient-reported outcomes represent 1 of the most important measures for evaluating the effectiveness of treatments of FI. However, these outcome measures must have evidence of reliability and validity to be useful in assisting patients' and clinicians' understanding of the impact of treatment. Responsiveness is an aspect of construct validity and is determined by evaluating the relationship between changes in clinical and patient-based end points and changes in outcome scores over time using observational studies or clinical trials. 13 Responsiveness is demonstrated by showing that scale's scores are sensitive to actual changes in health status as demonstrated in Table 2 . Although responsiveness is a key component to establishing a scale's construct validity, it is also important to determine the MID to assist in interpreting statistically significant results in clinical trials. Thus, responsiveness represents the instrument's ability to detect changes, whereas the MID denotes the smallest score or change in score that would likely be important from the patient's or clinician's perspective. In the 17, 18 This study has determined that reasonable estimates of MID are 4, 11 and 5, 18 and 8, and 3 points for the FISI, CRADI (long and short versions), CRAIQ (long and short versions), and MMHQ, respectively. Statistically significant improvements on these scales that meet these thresholds are likely to be clinically important and would assist the patient and physician in making treatment decisions. 12, 19 Because no one method for determining MID has been shown to be superior, we used a combination of methods including 2 anchor-based approaches and 2 distribution-based approaches to determine the MID for each scale. The application of multiple methods to determine the MID in a specific patient population almost always results in a range of values for the MID as seen in this study. This integrated approach using multiple methods is referred to as triangulation (ie, examining multiple values from different approaches and converging on a single MID value or narrow range of values). 13 Once the different MID estimates are determined, they may be graphed 13, 20 to depict the ranges of estimates with a single MID value (or narrow range of MID values) determined for each scale with the anchor-based estimates assigned the most weight. 13 For the primary anchor-based approach, we used a Global Impression of Change scale, the most commonly used type of anchor for MID determination, which represents the best measure of change from an individual perspective. 13 We chose to use the anchor-based method to determine the MID because it is recommended that the patient's perspective be given the most weight, although the clinician's perspective should also be considered. For the CRADI, CRAIQ, and MMHQ, we also used a second anchor, the FISI, which revealed similar results to those of the Global Impression of Change. When it is difficult or there is uncertainty about which MID may be best, it is recommended to base the final selection of MID values on some systematic review and evaluation process such as the modified Delphi method for achieving consensus, which we did not have to use in this study. 13 These anchor-based estimates were subsequently supported using 2 distribution-based estimates, effect size (1/2 SD), and 1 SEM. Distribution-based methods are anchor free and convey the notion that an MID can be estimated based on the distribution of observed scores. 13 It is important to distinguish distribution-based from anchor-based methods; distribution-based methods are simply a way of expressing responsiveness in that they describe an observed change using a standardized metric, and they provide some insight into how large or small that change is. Distributionbased methods, unlike anchor-based methods, do not inform us about whether the observed change is important from the patient's or clinician's perspective thus representing an MID. Nevertheless, there are increasing body of evidence and growing consensus that an effect size of 0.5 (or change of 1/2 SD) is a conservative estimate that is likely to be clinically significant across different patient-reported questionnaires and that in the absence of other 21, 22 The MIDs for each scale using the anchor-based approach are, as predicted, less than that for 0.5 SD approach, a conservative estimate for MID, and consistent with the one estimated by using the 1 SEM distribution-based approach. Therefore, the distribution-based methods for determining MID support the MID derived from the anchor-based approach.
The strengths of this study are the use of multiple approaches to triangulate MID estimates, the use of validated and widely accepted patient-reported FI outcome measures, and the use of a longitudinal prospective cohort of subjects with FI who were treated with the variety of treatment options per usual care. Usual care cohort studies, such as ABBI, are suited for MID determination because mild to moderate treatment effects are more common than those seen in randomized, controlled clinical trials. No change category represents the subjects whose maximum level change in any of FI types (solid, liquid, mucus, and gas) is zero (eg, 6 to 6, 5 to 5I). One-level improvement category represents the subjects whose maximum level improvement in any of FI types (solid, liquid, mucus, gas) is 1 (eg, 6 to 5, 5 to 4, 4 to 3, 3 to 2, 2 to 1).
Two-level improvement category represents the subjects whose maximum level improvement in any of FI types (solid, liquid, mucus, gas) is 2 (eg, 6 to 4, 5 to 3, 4 to 2, 3 to 1). The most significant limitation in this study is the small sample size in the no change and a little better groups (n = 38) that was used for the anchor-based approach resulting in wide CIs around the MID for each scale. This is largely attributable to the relatively small sample sizes within the global rating of change categories of no change and a little better combined with missing data on several of the scales. Similar to virtually every measure used in medicine, all patient-reported outcome measures include some measurement error. One needs confidence that observed changes in scores over time with treatment or disease progression are not primarily attributable to error. 13 Confidence in the MID values of each scale from this study should evolve over time through additional research on different populations and contextual characteristics. As with other aspects of construct validity, responsiveness and the MID value are confirmed based on accumulating evidence from multiple studies, and with additional data, we can be more confident in the MID value. 13 The second limitation is that anchor-based approaches are 1 measure of the patient's perspective (global rating of change), but the study did not include any objective clinical measures of FI frequency or severity such as incontinent episodes recorded on a bowel diary. The use of these types of objective measures of FI might strengthen the validity of our findings, and future studies should incorporate these if possible. In addition, our MID values for the CRADI, CRAQI, and MMHQ when using the Global Impression of Change scale were approximately half the value of those generated using the degree of improvement in FI severity level as the anchor. Possible explanations for this may be that changes in symptom severity scales, such as FISI, have a lower degree of association with changes in quality of life scores when compared with global impression scales or that our sample size is again simply too low to determine if the resulting MIDs are actually different using the 2 types of scales as anchors. Finally, questionnaires for this study were administered by telephone, and MIDs may differ if questionnaires are administered in person.
From this study, we recommend that reasonable estimates of MID are 4, 11 and 5, 18 and 8, and 3 points for the FISI, CRADI (long and short versions), CRAIQ (long and short versions), and MMHQ, respectively. These MID estimates may provide the basis for interpreting clinical trial results and help clinicians and patients understand the effects of treatment and patient functioning in those with FI. These values may also be identified a priori by researchers in sample size planning for clinical trials of FI. When caring for patients with FI in routine clinical care or during observational studies or clinical trials, statistically significant improvements that meet or exceed these MID thresholds should be considered clinically important. However, some patients with changes in scores less than these estimates may perceive clinically important improvements. The values for these MID estimates should be refined with accumulating evidence from future studies.
